Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical stage biopharmaceutical company focused on developing once-daily tablets for the treatment of ADHD and anxiety, with a potential approval for its novel drugs in late 2026 and commercialization in early 2027. The company's partnership with Prasco, sufficient cash to support operations, and extended IP runway are positive long-term indicators. However, there are risks such as balance sheet and liquidity concerns, competition, and regulatory approval uncertainties that could impact the company's future success. Despite these risks, Ascendiant Capital Markets, LLC has a Buy rating for Cingulate with a 12-month price target of $9 per share.

Bears say

Cingulate is a clinical-stage biopharmaceutical company that focuses on the development of products for the treatment of ADHD and other therapeutic areas using their proprietary drug delivery platform technology. Despite reporting a net loss of $5.9M for the three months ending June 30, 2026, with a cash runway until mid-2027, our DCF models yielded an equity value of $168M and a price target of $9 per share, assuming 18.02M shares outstanding at the end of 2Q27. However, there are risks that could impede shares from achieving our price target, such as regulatory setbacks, slower market penetration of their lead candidate, and potential dilution risk. Additionally, the constantly changing global drug pricing and reimbursement environment could have major ramifications for the company.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.